# IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction

> **NCT01007461** · PHASE2 · WITHDRAWN · sponsor: **Mallinckrodt**

## Conditions studied

- ST-Segment Elevation Myocardial Infraction

## Interventions

- **DRUG:** Sodium Sulfide (Na2S) for Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01007461
- **Lead sponsor:** Mallinckrodt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision. Non-safety related
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007461, "IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01007461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*